Gyre Therapeutics Statistics Share Statistics Gyre Therapeutics has 90.76M
shares outstanding. The number of shares has increased by 5.75%
in one year.
Shares Outstanding 90.76M Shares Change (YoY) 5.75% Shares Change (QoQ) 0.48% Owned by Institutions (%) 3.02% Shares Floating 16.2M Failed to Deliver (FTD) Shares 3,547 FTD / Avg. Volume 3.31%
Short Selling Information The latest short interest is 1.62M, so 1.78% of the outstanding
shares have been sold short.
Short Interest 1.62M Short % of Shares Out 1.78% Short % of Float 10.64% Short Ratio (days to cover) 16
Valuation Ratios The PE ratio is 85.2 and the forward
PE ratio is 27.07.
Gyre Therapeutics's PEG ratio is
-0.78.
PE Ratio 85.2 Forward PE 27.07 PS Ratio 9.74 Forward PS 3.7 PB Ratio 16.26 P/FCF Ratio -172.88 PEG Ratio -0.78
Financial Ratio History Enterprise Valuation Gyre Therapeutics has an Enterprise Value (EV) of 1.02B.
EV / Sales 9.64 EV / EBITDA 57.22 EV / EBIT -279.99 EV / FCF -171.16
Financial Position The company has a current ratio of 3.32,
with a Debt / Equity ratio of 0.03.
Current Ratio 3.32 Quick Ratio 2.99 Debt / Equity 0.03 Debt / EBITDA 0.09 Debt / FCF -0.27 Interest Coverage 0
Financial Efficiency Return on Equity is 19.09% and Return on Invested Capital is 11.61%.
Return on Equity 19.09% Return on Assets 9.64% Return on Invested Capital 11.61% Revenue Per Employee $182.65K Profits Per Employee $20.87K Employee Count 579 Asset Turnover 0.84 Inventory Turnover 0.61
Taxes Income Tax 5.32M Effective Tax Rate 22.91%
Stock Price Statistics The stock price has increased by -38.61% in the
last 52 weeks. The beta is 2.2, so Gyre Therapeutics's
price volatility has been higher than the market average.
Beta 2.2 52-Week Price Change -38.61% 50-Day Moving Average 7.6 200-Day Moving Average 9.19 Relative Strength Index (RSI) 48.78 Average Volume (20 Days) 107,007
Income Statement In the last 12 months, Gyre Therapeutics had revenue of 105.76M
and earned 12.09M
in profits. Earnings per share was 0.14.
Revenue 105.76M Gross Profit 101.87M Operating Income 16.16M Net Income 12.09M EBITDA 17.82M EBIT 16.23M Earnings Per Share (EPS) 0.14
Full Income Statement Balance Sheet The company has 11.81M in cash and 1.6M in
debt, giving a net cash position of 10.21M.
Cash & Cash Equivalents 11.81M Total Debt 1.6M Net Cash 10.21M Retained Earnings -73.45M Total Assets 152.65M Working Capital 74.36M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -3.64M
and capital expenditures -2.31M, giving a free cash flow of -5.96M.
Operating Cash Flow -3.64M Capital Expenditures -2.31M Free Cash Flow -5.96M FCF Per Share -0.07
Full Cash Flow Statement Margins Gross margin is 96.33%, with operating and profit margins of 15.28% and 11.43%.
Gross Margin 96.33% Operating Margin 15.28% Pretax Margin 21.95% Profit Margin 11.43% EBITDA Margin 16.85% EBIT Margin 15.28% FCF Margin -5.63%
Dividends & Yields GYRE does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 1.17% FCF Yield -0.58%
Dividend Details Analyst Forecast The average price target for GYRE is $18,
which is 139.4% higher than the current price. The consensus rating is "Buy".
Price Target $18 Price Target Difference 139.4% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number 1.54 Graham Upside -79.52%
Stock Splits The last stock split was on Oct 31, 2023. It was a
backward
split with a ratio of 1:15.
Last Split Date Oct 31, 2023 Split Type backward Split Ratio 1:15
Scores Altman Z-Score 17.91 Piotroski F-Score 4
